{"id":"dabigatran-clopidogrel","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Gastrointestinal hemorrhage"}]},"_chembl":{"chemblId":"CHEMBL1771","moleculeType":"Small molecule","molecularWeight":"321.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dabigatran directly inhibits thrombin (Factor IIa), preventing the conversion of fibrinogen to fibrin and blocking the coagulation cascade. Clopidogrel irreversibly inhibits the P2Y12 adenosine diphosphate receptor on platelets, preventing platelet aggregation. Together, this combination provides both anticoagulation and antiplatelet activity for thrombotic prevention.","oneSentence":"This combination uses dabigatran (a direct thrombin inhibitor) and clopidogrel (a P2Y12 platelet inhibitor) together to provide dual anticoagulant and antiplatelet effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:31:53.709Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome or post-percutaneous coronary intervention with atrial fibrillation"}]},"trialDetails":[{"nctId":"NCT03568890","phase":"PHASE4","title":"Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2018-09-01","conditions":"Left Atrial Appendage Closure, Thrombosis, Stroke","enrollment":510},{"nctId":"NCT05387954","phase":"PHASE3","title":"PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-07","conditions":"Cryptogenic Ischemic Stroke, Patent Foramen Ovale","enrollment":792},{"nctId":"NCT04809818","phase":"PHASE1","title":"A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects","status":"COMPLETED","sponsor":"Lumosa Therapeutics Co., Ltd.","startDate":"2021-03-21","conditions":"Acute Ischemic Stroke","enrollment":65},{"nctId":"NCT07358416","phase":"","title":"Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Petrovsky National Research Centre of Surgery","startDate":"2025-05-01","conditions":"Thrombosis, Bleeding, Cerebral Hypoxia During and/or Resulting From A Procedure","enrollment":500},{"nctId":"NCT04045665","phase":"PHASE3","title":"Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-12-13","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":3200},{"nctId":"NCT03463317","phase":"PHASE4","title":"Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-02-28","conditions":"Atrial Fibrillation","enrollment":912},{"nctId":"NCT06983795","phase":"","title":"Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-07","conditions":"Ischemic Stroke, Patent Foramen Ovale","enrollment":1000},{"nctId":"NCT06449469","phase":"NA","title":"The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-05-01","conditions":"Aortic Valve Stenosis, Cardiovascular Diseases, Heart Diseases","enrollment":352},{"nctId":"NCT03062319","phase":"PHASE4","title":"Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis","status":"TERMINATED","sponsor":"National Hospital Organization Osaka National Hospital","startDate":"2017-04-06","conditions":"Ischemic Stroke, Atrial Fibrillation, Atherothrombosis","enrollment":321},{"nctId":"NCT04847752","phase":"","title":"Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2021-03-01","conditions":"Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)","enrollment":1000},{"nctId":"NCT06058130","phase":"NA","title":"Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09-29","conditions":"Acute Ischemic Stroke, Atrial Fibrillation, Stenosis, Carotid","enrollment":2171},{"nctId":"NCT03961334","phase":"PHASE3","title":"MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2019-12-05","conditions":"Stroke, Ischemic","enrollment":620},{"nctId":"NCT03234114","phase":"PHASE4","title":"Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2018-02-03","conditions":"Acute Coronary Syndrome (ACS), Non-valvular Atrial Fibrillation (NVAF)","enrollment":3746},{"nctId":"NCT03942913","phase":"","title":"Prospective Real-world Registry Describing Treatment Regimens","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2019-10-10","conditions":"Subject Under Anticoagulant","enrollment":573},{"nctId":"NCT04695106","phase":"PHASE4","title":"Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2021-10-25","conditions":"Atrial Fibrillation, Antithrombotic Therapy, Acute Coronary Syndrome","enrollment":2230},{"nctId":"NCT04688723","phase":"PHASE4","title":"Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI","status":"UNKNOWN","sponsor":"Zuyderland Medisch Centrum","startDate":"2020-12-23","conditions":"Coronary Artery Disease, Myocardial Ischemia, Myocardial Infarction","enrollment":1000},{"nctId":"NCT04518735","phase":"","title":"Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2020-04-01","conditions":"Covid19","enrollment":1707},{"nctId":"NCT04291287","phase":"","title":"Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)","status":"UNKNOWN","sponsor":"Scientific Institute San Raffaele","startDate":"2020-01-25","conditions":"Atrial Fibrillation, Myocardial Infarction, Anticoagulant-induced Bleeding","enrollment":1500},{"nctId":"NCT02635230","phase":"","title":"What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.","status":"UNKNOWN","sponsor":"R&D Cardiologie","startDate":"2014-06","conditions":"Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes","enrollment":2200},{"nctId":"NCT03970421","phase":"","title":"Severity Factors and Needed Observation Time at ED of Patients Wih Head Injury","status":"UNKNOWN","sponsor":"Hospital El Escorial","startDate":"2019-06","conditions":"Head Injury Other, Length of Stay, Delayed Complications","enrollment":300},{"nctId":"NCT02606552","phase":"PHASE4","title":"Safety and Efficacy of Left Atrial Appendage Closure Versus Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation Due to Complex Coronary Artery Disease","status":"TERMINATED","sponsor":"Yonsei University","startDate":"2016-07-20","conditions":"Atrial Fibrillation, Coronary Artery Disease","enrollment":9},{"nctId":"NCT03536611","phase":"PHASE4","title":"Dabigatran Versus Warfarin With NVAF Who Undergo PCI","status":"UNKNOWN","sponsor":"Shenyang Northern Hospital","startDate":"2018-09-01","conditions":"Atrial Fibrillation, Coronary Artery Disease","enrollment":1120},{"nctId":"NCT02164864","phase":"PHASE3","title":"Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-07-22","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":2725},{"nctId":"NCT01962545","phase":"PHASE4","title":"Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study","status":"COMPLETED","sponsor":"Satoshi Shizuta","startDate":"2013-11-05","conditions":"Atrial Fibrillation, Coronary Artery Disease","enrollment":690},{"nctId":"NCT03327350","phase":"","title":"WATCHMAN for Second Prevention of Stroke (WASPS)","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2017-11-05","conditions":"Atrial Fibrillation, Stroke","enrollment":400},{"nctId":"NCT00562289","phase":"PHASE3","title":"Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2007-12","conditions":"Ischemic Stroke, Patent Foramen Ovale, Atrial Septal Aneurysm","enrollment":664},{"nctId":"NCT02723981","phase":"PHASE4","title":"COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials","status":"WITHDRAWN","sponsor":"IHF GmbH - Institut für Herzinfarktforschung","startDate":"2016-04","conditions":"Stable Angina, Unstable Angina, STEMI","enrollment":""},{"nctId":"NCT01852162","phase":"NA","title":"Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy","status":"COMPLETED","sponsor":"University of Florida","startDate":"2012-02","conditions":"Coronary Artery Disease","enrollment":35},{"nctId":"NCT01352702","phase":"PHASE4","title":"Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation","status":"TERMINATED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2011-05","conditions":"Coronary Heart Disease, Atrial Fibrillation, Acute Coronary Syndrome","enrollment":46},{"nctId":"NCT02309970","phase":"","title":"Perfusion Computer Tomography: Imaging and Clinical Validation Following Reperfusion Therapy in Acute Ischaemic Stroke","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2014-12","conditions":"Ischemic Stroke","enrollment":90},{"nctId":"NCT01511939","phase":"PHASE3","title":"Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants","status":"COMPLETED","sponsor":"Nathan Wei, MD, FACP, FACR:","startDate":"2012-02","conditions":"Osteoarthritis of the Knee, Coagulopathy","enrollment":22},{"nctId":"NCT02171598","phase":"PHASE1","title":"Investigation of the Impact of Concomitant Use of Multiple Doses of Clopidogrel With Multiple Doses of Dabigatran Etexilate on the Pharmacokinetic and Pharmacodynamic Parameters in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-02","conditions":"Healthy","enrollment":44},{"nctId":"NCT00621855","phase":"PHASE2","title":"RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-03","conditions":"Coronary Disease","enrollment":1878}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dabigatran + clopidogrel","genericName":"Dabigatran + clopidogrel","companyName":"Zuyderland Medisch Centrum","companyId":"zuyderland-medisch-centrum","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses dabigatran (a direct thrombin inhibitor) and clopidogrel (a P2Y12 platelet inhibitor) together to provide dual anticoagulant and antiplatelet effects. Used for Acute coronary syndrome or post-percutaneous coronary intervention with atrial fibrillation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}